Thiopurine EnhAnced Maintenance Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

March 31, 2020

Study Completion Date

April 30, 2020

Conditions
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Interventions
DRUG

Thioguanine (oral)

Addition of incremental doses of oral Thioguanine to oral daily 6-mercaptopurine and oral weekly methotrexate maintenance therapy of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Oral 6-thioguanine is added at a starting dose of 2.5 mg/m.sq. with dose increments of 2.5 mg/m.sq. at two weeks intervals until a maximum dose of 12.5 mg/m.sq. of 6-thioguanine is given or dose-limiting toxicity occurs.

Trial Locations (4)

2100

Department of Pediatrics, Rigshospitalet, Copenhagen

Rigshospitalet, Department of Hematology, Copenhagen

5000

Odense University Hospital, Dept. Pediatric Oncology, Odense

8200

Aarhus University Hospital Skejby, Skejby

All Listed Sponsors
collaborator

Danish Child Cancer Foundation

OTHER

collaborator

Nordic Society for Pediatric Hematology and Oncology

OTHER

lead

Kjeld Schmiegelow

OTHER

NCT02912676 - Thiopurine EnhAnced Maintenance Therapy | Biotech Hunter | Biotech Hunter